Clinical Trial Search

Primary: Area Under the Curve From 0-12 Hours (AUC[0-12h]) of the Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) After a Single Dose of MF/F MDI With Spacer…

Primary: Rise in Systolic Blood Pressure Over the First 10 Minutes of Use Compared to Baseline — 5.9; 12.9 mm Hg

Primary: Change in Body Mass Index (BMI) — 0.315; 0.190 kilograms per meter squared — p=0.36

Primary: Objective Response Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) — 66.7; 40.6 Percentage of patients

Primary: Number of Subjects With Adverse Events, Hospitalizations, Thrombotic Events, Treatment-emergent C1 INH Antibodies, Post-baseline Toxicity Grade Increases in Clinical…

Primary: Estimation of the Proportion of Progression-free Patients at 16 Wks. — 0 percentage of participants

Primary: Procedure Time — 5.9; 8.1 minutes

Primary: Overall Survival — .64 proportion surviving at 4 years

Primary: Response Rate (Complete Response [CR] Plus Partial Response [PR]) of Clofarabine Plus Cytarabine in Patients With Relapsed/Refractory AML, Untreated MDS, CML in Blast…

Primary: Attrition (Number of Therapy Sessions Attended) — 15.4; 13.7 Number of Sessions — p=0.003

Primary: Total Eye Symptoms Score Difference — 6; 0; 2.5; 1.5 units on a scale — p=<0.001

Primary: Change in ADHD-IV Rating Scale Total Score — -13.2; -5.8 units on a scale

Primary: Percentage of Participants Who Achieved an Objective Confirmed Complete or Partial Overall Response — 62.5 Percentage of participants

Primary: Progression-Free Survival — 78; 52 percentage of participants

Primary: S- and R- Enantiomers of Warfarin (S-warfarin and R-warfarin) Area Under the Plasma Concentration-time Curve (AUC) From 0 to 12 Hours. — 2,250; 2,230; 2,850; 2,930 ng/ml*h